Stephen H. Barnes, the Chief Financial Officer of Accolade, Inc. (NASDAQ:ACCD), recently executed a series of stock transactions involving the company's common stock. According to a recent SEC filing, Barnes sold 223 shares on November 12, 2024, at an average price of $3.638 per share, totaling approximately $811. This sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs).
Additionally, Barnes acquired 770 shares of common stock on November 11, 2024, through the conversion of RSUs, which were converted at no cost. Following these transactions, Barnes directly owns 204,999 shares of Accolade's common stock.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been the focus of several analyst adjustments. Wells Fargo (NYSE:WFC) revised the company's price target downwards to $6.00, citing concerns over delayed deal closures that may affect future growth. However, the firm maintained an Equal Weight rating, indicating a balanced risk-reward profile. On the other hand, Stephens, Canaccord Genuity, Truist Securities, and BofA Securities have also revised their price targets while keeping Buy ratings. These adjustments follow Accolade's strong second-quarter results for 2025, which surpassed revenue expectations with a total of $106.4 million, and its confirmed fiscal year 2025 revenue guidance between $460 million to $475 million.
In other recent developments, Accolade's management has expressed optimism about a strong pipeline across employers, health plans, and government segments. The company's competitive edge in the expert medical opinion (EMO) product market and its successful management of marketing expenses have also been highlighted. However, slower revenue growth is anticipated in fiscal year 2026 due to staggered launches.
These updates come as Accolade continues to navigate its current business dynamics, particularly the uncertainties surrounding the finalization of key contracts. The company's revenue targets are still within reach if it achieves moderate growth in its Annual Contract Value (ACV). Despite these challenges, Accolade's recent financial performance and strategic direction have been recognized by multiple analyst firms.
InvestingPro Insights
To provide additional context to Stephen H. Barnes' recent stock transactions, it's worth examining some key financial metrics and insights from InvestingPro for Accolade, Inc. (NASDAQ:ACCD).
According to InvestingPro data, Accolade's market capitalization stands at $300.4 million, reflecting its current position in the healthcare technology sector. The company's revenue for the last twelve months as of Q2 2025 was $441.03 million, with a revenue growth of 16.04% over the same period. This growth indicates that Accolade is expanding its business operations despite challenging market conditions.
However, it's important to note that Accolade is not currently profitable. The company reported an adjusted operating income of -$93.68 million for the last twelve months, with an operating income margin of -21.24%. This aligns with an InvestingPro Tip stating that analysts do not anticipate the company will be profitable this year.
Another relevant InvestingPro Tip highlights that Accolade's stock price movements are quite volatile. This is evident in the company's price performance, with a significant 8.8% return over the last week, but a substantial -48.54% return over the past six months. This volatility could explain why executives like Barnes might engage in stock transactions for tax purposes or portfolio management.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights. In fact, there are 7 more InvestingPro Tips available for Accolade, which could provide valuable context for understanding the company's financial position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.